Answers are grounded in this paper and cite their sources.
PipISB [N‐(4‐fluoro‐benzyl)‐4‐(3‐(piperidin‐1‐yl)‐indole‐1‐sulfonyl)benzamide, 9] was identified as a selective high potency CB1 receptor ligand. Here we describe the labeling of 9 with positron‐emitters to provide candidate radioligands for imaging brain CB1 receptors with positron emission tomography (PET). The radiolabeling of 9 was achieved by two methods, method A with carbon‐11 and method B with fluorine‐18. In method A, [11C]9 was prepared in one step from [11C]carbon monoxide, itself prepared from cyclotron‐produced [11C]carbon dioxide. In method B, [18F]9 was prepared from cyclotron‐produced [18F]fluoride ion in a two‐stage, four‐step synthesis with [18F]4‐fluoro‐benzyl bromide as a labeling agent. The radiosynthesis time for method A was 44 min; decay‐corrected radiochemical yields (RCYs) from [11C]carbon monoxide ranged from 3.1 to 11.6% and specific radioactivities ranged from 21 to 67 GBq/µmol. The radiosynthesis time for method B was 115 min; RCYs from [18F]fluoride ion ranged from 1.5 to 5.6% and specific radioactivities ranged from 200 to 348 GBq/µmol. With these methods, [11C]9 and [18F]9 may be prepared in adequate activity and quality for future evaluation as PET radioligands.
No takes yet. Share an insight, caveat, or question.
Donohue et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: